Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/24226
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiberopoulos, E. N.en
dc.contributor.authorDaskalopoulou, S. S.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorWierzbicki, A. S.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T19:39:14Z-
dc.date.available2015-11-24T19:39:14Z-
dc.identifier.issn0300-7995-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24226-
dc.rightsDefault Licence-
dc.subjectCoronary Artery Disease/etiology/prevention & controlen
dc.subjectFatty Acids, Monounsaturated/adverse effects/*pharmacology/therapeutic useen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/adverseen
dc.subjecteffects/*pharmacology/therapeutic useen
dc.subjectHypercholesterolemia/complications/*drug therapyen
dc.subjectIndoles/adverse effects/*pharmacology/therapeutic useen
dc.subjectLipids/*blooden
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectTreatment Outcomeen
dc.titleA review of the lipid-related effects of fluvastatinen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1185/030079905X26261-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15801994-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1185/030079905X26261-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractBACKGROUND: Statin therapy has been shown to significantly decrease vascular events and overall mortality in primary and secondary prevention trials. This review considers the pharmacology, nonlipid-lowering effects and clinical trial evidence of fluvastatin based on a survey of PubMed entries. FINDINGS: Recent clinical data show that treatment with fluvastatin is associated with a variety of benefits in different high-risk populations along with a good safety profile. Fluvastatin exerts non-lipid lowering-associated pleiotropic effects in both clinical and experimental studies. Furthermore, an extended-release formulation of fluvastatin with a favourable pharmacokinetic profile is available. CONCLUSION: Treatment with fluvastatin offers a convenient, safe and evidence-based approach to managing dyslipidaemias and preventing vascular events.en
heal.journalNameCurrent Medical Research and Opinionen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons